Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC2731 in Chronic Sinusitis with Nasal Polyps
NCT06036927Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2023
- Primary completion
- Feb 2025
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bosakitug in chronic rhinosinusitis with nasal polyps (CRSwNP) (3 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Nasal Polyp Score at 24 weeks. Started Dec 2023; status: completed.
02
Drugs
bosakitug
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06036927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06036927.